MAYNE PHARMA GROUP LIMITED — M&A Activity 2013

Jul 1, 2013

==> picture [116 x 45] intentionally omitted <==

ASX Announcement

MAYNE PHARMA ANNOUNCES THE ACQUISITION OF LIBERTAS

• Expands US generic product portfolio and pipeline

• Enhanced network of manufacturing and development partners

• Stronger US commercial capability to support growing product portfolio

• Acquisition expected to be immediately EPS accretive

2 July 2013, Melbourne Australia: Mayne Pharma Group Limited (Mayne Pharma) is pleased to announce that it has acquired US-based Libertas Pharma Inc. (Libertas).

Libertas is a generic pharmaceutical company headquartered in Atlanta, Georgia that distributes and markets a range of niche products in the US. Libertas is highly complementary to the Metrics Products division having 6 marketed ANDA[1] products and 2 pipeline ANDAs distributed through the same retail pharmacy channel with no product overlap.

Commenting on the acquisition, Mayne Pharma’s CEO, Mr Scott Richards said “We are very pleased to have completed the Libertas acquisition which was acquired by way of an upfront payment comprising cash and a small scrip component to owner and founder, Mr Chris Schneider, and a three year performance based earn-out which will be funded from operating cash. The acquisition is favourably structured such that more than 60% of the total purchase price is performance based.”

“Libertas fits well with the Metrics business and further strengthens our US generics franchise, which will now distribute 15 generic ANDA products and have more than 20 products in various stages of development, including 7 products filed with the US FDA. Importantly, the acquisition is expected to be earnings accretive in FY14 and is well positioned to deliver further incremental growth to the US business.”

“Chris Schneider will be joining Mayne Pharma’s US leadership team as Vice President, Sales & Marketing. Chris has a proven track record of sales leadership and success in the pharmaceutical industry and I am certain that he will play a key role in executing our business strategy and further accelerating the growth of the Metrics Products division.”

For further information contact: Scott Richards +61 8 8209 2410 Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

1 ANDA – Abbreviated New Drug Application

==> picture [125 x 126] intentionally omitted <==

Page 1

==> picture [116 x 45] intentionally omitted <==

ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes globally; either directly or through distribution partners and also provides contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

==> picture [125 x 126] intentionally omitted <==

Page 2